SCHEMBL893786

SCHEMBL893786

[c]1n[nH]cc1-c1cnccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.38
CYP2D6 P10635 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
METAP2 P50579 1/20 0.33
RECQL P46063 2/20 0.33
HTT P42858 1/20 0.33
PIM1 P11309 1/20 0.32
P2RX7 Q99572 1/20 0.32
CYP1A2 P05177 1/20 0.32
HSP90AA1 P07900 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
CHRNB2 P17787 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA7 P36544 1/20 0.30
CHRNA4 P43681 1/20 0.30
ROCK2 O75116 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331328 0.74 KDM4E (0.50) NISCHMETAP2HTTCYP1A2HSP90AA1
SCHEMBL78566 0.68 NISCH (0.50) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL29454745 0.68 NISCH (0.50) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL29598957 0.68 NISCH (0.50) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL3640139 0.66 NISCH (0.48) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL9794662 0.66 NISCH (0.48) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL14053846 0.66 NISCH (0.48) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL31372462 0.66 NISCH (0.48) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL359859 0.65 METAP2 (0.37) NISCHCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL15809743 0.65 NISCH (0.34) NISCHCYP2D6CYP19A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468367-B2 Ethylene diamine derivatives and their use as orexin-receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2008-12-23 US claimed
EP-3481831-A1 NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2019-05-15 EP disclosed
WO-2018009017-A1 NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2018-01-11 WO disclosed
US-20150031685-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS Dr. Reeddy's Laboratories Ltd. (IN) 2015-01-29 US disclosed
CN-102834390-B Diazinylpyrazolyl compounds BAYER CROPSCIENCE AG 2014-11-12 CN disclosed
CN-102834390-B Diazinylpyrazolyl compounds BAYER CROPSCIENCE AG 2014-11-12 CN disclosed
US-20140243340-A1 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF ABBVIE INC. (US) 2014-08-28 US disclosed
US-8629273-B2 Diazinylpyrazolyl compounds BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-14 US disclosed
US-8629273-B2 Diazinylpyrazolyl compounds BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-14 US disclosed
US-8629273-B2 Diazinylpyrazolyl compounds BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-01-14 US disclosed
EP-1289985-B1 BETA-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE ORTHO MCNEIL PHARM INC (US) 2003-12-10 EP disclosed
US-6635638-B2 Treatment of sexual dysfunction, cardiovascular system disorders ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-10-21 US disclosed
US-20030166641-A1 Beta-carboline derivatives useful as inhibitors of phosphodiesterase SUI ZHIHUA (US) 2003-09-04 US disclosed
EP-1296981-A2 SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS Ortho-McNeil Pharmaceutical, Inc. (US) 2003-04-02 EP disclosed
EP-1289985-A2 BETA-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE Ortho-McNeil Pharmaceutical, Inc. (US) 2003-03-12 EP disclosed
US-6492358-B2 FOR TREATMENT OF SEXUAL DISORDERS, MALE ERECTILE DYSFUNCTION ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-12-10 US disclosed
US-20020010189-A1 beta-carboline derivatives useful as inhibitors of phosphodiesterase ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-01-24 US disclosed
US-20020010183-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-01-24 US disclosed
WO-2001087038-A2 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-11-22 WO disclosed
WO-2001087882-A2 SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031685-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS OPRK1, OPRL1, OPRD1 NISCH 2120/4885CYP2D6 657/4885CYP19A1 953/4885
US-20020010189-A1 beta-carboline derivatives useful as inhibitors of phosphodiesterase PDE3B, PDE5A, PDE3A NISCH 1910/4885CYP2D6 961/4885CYP19A1 72/4885
US-20020010183-A1 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors PDE5A, PDE3A, PDE3B NISCH 2707/4885CYP2D6 456/4885CYP19A1 24/4885
US-20030166641-A1 Beta-carboline derivatives useful as inhibitors of phosphodiesterase PDE3B, PDE5A, PDE3A NISCH 1910/4885CYP2D6 961/4885CYP19A1 72/4885
US-20140243340-A1 CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF CYP3A43, CYP3A5, POR NISCH 842/4885CYP2D6 5/4885CYP19A1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.